Post Profile






Why tumors evade immunotherapy

(Max Delbrück Center for Molecular Medicine in the Helmholtz Association) Immunotherapy is a new and highly promising form of treatment for cancer, but in many patients, tumors recur. The members of a research team from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, the Berlin Institute of Health, and Charité -- Universitätsmedizin Berlin now explain why some tumors recur and how this can be prevented.
read more

share

Related Posts


Researchers Find Up to One-Quarter of Lung Cancer Patients May Be Ineligible for Immunotherapy

Health : Newswise Medical News

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center's Harold C. Sim...

Penn Medicine Two-Step Ovarian Cancer Immunotherapy Made from Patients' Own Tumor Benefits Three Quarters of Trial Patients

Health : Newswise Medical News

As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission -- according research from the Perelman School of Me...

National Cancer Institute Designated Cancer Center Featured Article: Yale Cancer Center Carves New Path in Immunotherapy

Health : Newswise Medical News

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

Memorial Sloan Kettering Cancer Center and Quest Diagnostics Partner to Advance Precision Medicine in Cancer Diagnosis and Treatment

Health : Newswise Medical News

Memorial Sloan Kettering Cancer Center and Quest Diagnostics announced a joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors. The goal is to use molecular labor...

Researchers at Albert Einstein College of Medicine Receive $2.6 Million NIH Grant to Develop Targeted Cancer Immunotherapies

Health : Newswise Medical News

Researchers, led by Steven Almo, Ph.D., and Chandan Guha, M.B.B.S., Ph.D., at Albert Einstein College of Medicine have received a five-year, $2.6 million NIH grant to make immunotherapy agents that are more precise and effective at ...

Comments


Copyright © 2016 Regator, LLC